• Je něco špatně v tomto záznamu ?

Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants

AS. Bhagavathula, K. Vidyasaga, EA. Gebreyohannes, W. Tesfaye

. 2022 ; 56 (7) : 820-830. [pub] 20211001

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, metaanalýza, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017848

OBJECTIVE: This study aimed to comprehensively evaluate the risk of gastrointestinal bleeding (GIB) with statin monotherapy or with concomitant warfarin use. DATA SOURCES: PubMed, Web of Science, and EMBASE (via Scopus) were searched for observational studies that reported the risk of GIB in adults on statin therapy or with concomitant warfarin use until August 28, 2021. STUDY SELECTION AND DATA EXTRACTION: Observational studies evaluating the risk of GIB in adults (age >18 years) on statin medication or concomitant use with warfarin were included. DATA SYNTHESIS: In all, 14 studies with a total of 5 235 123 participants, reporting 48 677 GIB events (43 734 from statin users and 4943 from users of statin combined with warfarin), were included in the analyses. The pooled analysis revealed no difference in the risk of GIB with statin monotherapy (relative risk [RR]: 0.65; 95% CI: 0.42-1.02) or concomitant statin + warfarin use (RR: 0.97; 95% CI: 0.91-1.02). Prior use of statin was not associated with GIB risk (RR: 0.88; 95% CI: 0.63-1.22), whereas a shorter duration of statin use (<5 years) was associated with a lower risk of GIB (RR: 0.42; 95% CI: 0.18-0.97). RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: This analysis provides strong evidence on the association between statin use (with/without warfarin) and risk of GIB. CONCLUSION: Statin alone or combined with warfarin was not significantly associated with either an increased or decreased risk of GIB. The GIB risk was significantly lower when statins were used for a short duration (<5 years). The putative relationship between statins and GIB in warfarin users warrant further investigation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017848
003      
CZ-PrNML
005      
20220804134423.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/10600280211049727 $2 doi
035    __
$a (PubMed)34595940
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bhagavathula, Akshaya Srikanth $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic
245    10
$a Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants / $c AS. Bhagavathula, K. Vidyasaga, EA. Gebreyohannes, W. Tesfaye
520    9_
$a OBJECTIVE: This study aimed to comprehensively evaluate the risk of gastrointestinal bleeding (GIB) with statin monotherapy or with concomitant warfarin use. DATA SOURCES: PubMed, Web of Science, and EMBASE (via Scopus) were searched for observational studies that reported the risk of GIB in adults on statin therapy or with concomitant warfarin use until August 28, 2021. STUDY SELECTION AND DATA EXTRACTION: Observational studies evaluating the risk of GIB in adults (age >18 years) on statin medication or concomitant use with warfarin were included. DATA SYNTHESIS: In all, 14 studies with a total of 5 235 123 participants, reporting 48 677 GIB events (43 734 from statin users and 4943 from users of statin combined with warfarin), were included in the analyses. The pooled analysis revealed no difference in the risk of GIB with statin monotherapy (relative risk [RR]: 0.65; 95% CI: 0.42-1.02) or concomitant statin + warfarin use (RR: 0.97; 95% CI: 0.91-1.02). Prior use of statin was not associated with GIB risk (RR: 0.88; 95% CI: 0.63-1.22), whereas a shorter duration of statin use (<5 years) was associated with a lower risk of GIB (RR: 0.42; 95% CI: 0.18-0.97). RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: This analysis provides strong evidence on the association between statin use (with/without warfarin) and risk of GIB. CONCLUSION: Statin alone or combined with warfarin was not significantly associated with either an increased or decreased risk of GIB. The GIB risk was significantly lower when statins were used for a short duration (<5 years). The putative relationship between statins and GIB in warfarin users warrant further investigation.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a antikoagulancia $x škodlivé účinky $7 D000925
650    _2
$a gastrointestinální krvácení $x chemicky indukované $x farmakoterapie $x epidemiologie $7 D006471
650    _2
$a lidé $7 D006801
650    12
$a statiny $x škodlivé účinky $7 D019161
650    12
$a warfarin $x škodlivé účinky $7 D014859
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Vidyasaga, Kota $u Kakatiya University, Warangal, India $1 https://orcid.org/0000000278660936
700    1_
$a Gebreyohannes, Eyob Alemayehu $u Division of Pharmacy, School of Allied Health, University of Western Australia, WA, Australia
700    1_
$a Tesfaye, Wubshet $u University of Canberra, Australian Capital Territory, Australia $1 https://orcid.org/0000000172082330
773    0_
$w MED00000437 $t The Annals of pharmacotherapy $x 1542-6270 $g Roč. 56, č. 7 (2022), s. 820-830
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34595940 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134417 $b ABA008
999    __
$a ok $b bmc $g 1821776 $s 1169091
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 56 $c 7 $d 820-830 $e 20211001 $i 1542-6270 $m The annals of pharmacotherapy $n Ann Pharmacother $x MED00000437
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace